The Crystal Structure of Orthocetamol Solved by 3D Electron Diffraction by Andrusenko, Iryna et al.
                          Andrusenko, I., Hamilton, V., Mugnaioli, E., Lanza, A., Hall, C.,
Potticary, J., Hall, S. R., & Gemmi, M. (2019). The Crystal Structure of
Orthocetamol Solved by 3D Electron Diffraction. Angewandte Chemie




Link to published version (if available):
10.1002/anie.201904564
Link to publication record in Explore Bristol Research
PDF-document
This is the accepted author manuscript (AAM). The final published version (version of record) is available online
via Wiley at https://doi.org/10.1002/anie.201904564 . Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
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Abstract: Orthocetamol is a regioisomer of the well-known pain 
medication paracetamol and a promising analgesic and an anti-
arthritic medicament itself. However, orthocetamol cannot be grown 
as single crystals suitable for X-ray diffraction, so its crystal structure 
has remained a mystery for more than a century. We report here the 
ab-initio structure determination of orthocetamol obtained by 3D 
electron diffraction, combining a low dose acquisition method and a 
dedicated single electron detector for recording the diffracted 
intensities. The structure is monoclinic, with a pseudo-tetragonal cell 
that favors multiple twinning on a scale of a few tens of nanometers. 
The successful application of 3D electron diffraction to orthocetamol 
introduces a new gold standard of total structure solution in all cases 
where X-ray diffraction and electron microscope imaging methods fail. 
Difficult and long-lasting crystallographic problems are often 
connected with the intractability of growing large single crystals 
suitable for X-ray diffraction. Either the compound cannot 
crystallize and exists only in molecular form, or available crystals 
are ordered and coherent only in domains not larger than a few 
hundreds of nanometers. High resolution transmission electron 
microscopy (TEM) provides in these cases a way to bypass the 
absence of long-range order by directly imaging single 
macromolecules (CryoEM), or nanometric crystal domains with 
atomic resolution (HREM imaging). However, if the molecule is 
too small (<100 kDa) or the nanocrystals are particularly beam 
sensitive and do not stand the electron dose necessary for HREM, 
the crystallographic problem remains unsolvable by imaging 
methods.  
The first experimental protocol for acquiring 3D electron 
diffraction (3D ED) data was proposed by Kolb et al. in 2007[1]. 
This method allows sampling intensity data through the whole 
reciprocal space without knowing the crystallographic orientation 
of the sample, as is instead necessary for conventional in-zone 
ED patterns. 3D ED development was initially prompted by the 
need for a fast and efficient procedure for ED data collection on 
beam sensitive organic materials. Eventually, it transpired that 
this method also significantly reduced dynamical scattering, long 
considered the bottleneck of ED. 3D ED has therefore proven to 
be extremely efficient for the structure determination of many 
kinds of nanocrystalline compounds, including minerals[2], 
functional materials[3], zeolites[4] and MOFs[5]. More recently, the 
availability of a new generation of detectors able to count the 
arrival of single electrons have led to the development of 
extremely low dose acquisition protocols, based on continuous 
sample rotation[6] or on precession-assisted nanobeam electron 
diffraction coupled with scanning transmission electron 
microscopy (STEM) crystal tracking[7]. Such modes allowed the 
structure determination of extremely beam sensitive materials, 
like prions[8] and macromolecules[6b, 7, 9].  
Continuous-rotation 3D ED, also referred to as MicroED, 
has been proven to be extremely efficient for structure 
determination of pharmaceuticals, without the need of growing 
large crystals.[10] However, to our knowledge all hitherto solved 
pharmaceuticals were test samples, whose structure had already 
been previously solved by X-ray diffraction. Orthocetamol (2-
acetamidophenol) is an ortho-substituted regioisomer of 
paracetamol (4-acetamidophenol), one of the most widely used 
pharmaceuticals in the world (Figure S1). The ubiquity comes 
from the fact that paracetamol acts as an effective analgesic.[11] 
One major drawback of paracetamol however is the 
hepatotoxicity; overdoses of paracetamol remain the leading 
cause of liver damage across the UK/USA/Europe. This has led 
directly to an increase in research into related structures, 
particularly orthocetamol, which has been shown to demonstrate 
lower hepatotoxicity.[12]  
Orthocetamol has also shown promise as an anti-arthritic 
treatment, a typical standard for inflammatory conditions, across 
a range of arthritic biomarkers, showing potential in not only 
halting progression of this disease, but in regulating the 
associated nociception.[13] Although both para- and meta-cetamol 
have solved crystal structures,[14] to-date there has been no 
structure of orthocetamol reported. Remarkably, orthocetamol 
was first reported in 1876,[15] i.e. before the discovery of X-rays. 
Therefore, this compound has existed for the entire history of 
crystallography with its structure unable to be determined either 
by single-crystal or powder methods. 
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Figure 1. Orthocetamol platelets under light microscopy. a) Typical aspect of 
pale brown pseudo-squared orthocetamol aggregates. b) Example of a platelet 
with internal contrast features and evidences of sector boundaries along 
diagonals. It is evident that the square sides are not straight, as would be 
expected for a single crystal. c) Zoom of a platelet angle showing the actual 
occurrence of different overgrowing domains. d) Zoom of a broken platelet 
border that reveals the tile arrangement of thin domains. 
Orthocetamol crystallizes as large quadrilateral platelets up 
to 300 µm in size (Figure 1). In fact, closer inspection reveals that 
the platelets are composed of a conglomeration of far smaller 
crystals (Figures S2 and S3). A few of these quadrilateral 
assemblies were therefore gently crushed and loaded on a 
carbon-coated Cu TEM grid. 3D ED data were collected at room 
temperature from eight fragments with size ranging from 500 nm 
to 2 μm (Figure S4). Data acquisition was performed stepwise 
using a parallel electron nanobeam of about 150 nm, while the 
crystal position was sequentially tracked in STEM mode.[7] Even 
fragments of few hundreds of nanometers show contrast features 
that suggest a certain degree of structural inhomogeneity. 
The reconstructed 3D ED data delivered a pseudo-
tetragonal primitive unit cell with parameters a = 7.4 Å and c = 
13.7 Å. Such a cell would conveniently host four orthocetamol 
molecules, in apparent agreement with the multiplicity of point 
groups 4 and -4. Nevertheless, all attempts to solve ab-initio and 
refine orthocetamol structure with a tetragonal space group failed. 
Indeed, cells obtained from different 3D ED data showed 
significant deviations of cell angles, and symmetry determination 
was further complicated by the appearance of weak intensities for 
reflections that would eventually result extinct in the final correct 
symmetry. Such ambiguities are common for ED, but for 
orthocetamol they were aggravated by the systematic occurrence 
of stacking disorder and nanotwinning at the scale of a few cell 
repetitions.  
 
Figure 2. Orthocetamol diffraction volume reconstructed on the basis of 3D ED 
data. a) View along a*.e Red arrows point columns of extinct reflections due to 
c-glide plane (h0l : l = 2n). Weak intensities are present due to residual 
dynamical effects and twinning. b) View along b*. c) View along c*, showing the 
typical chess-board pattern due to the lattice C-centering. d) View along the tilt 
axis of the acquisition, showing the sampled double-wedge of orthocetamol 
reciprocal space (from -60° to +60°). Cell edges are sketched in yellow. a* 
vector is in red, b* vector in green, c* vector in blue. Note that these are 
projections of a 3D diffraction volume and not conventional 2D in-zone 
diffraction patterns. 
On closer inspection, the data revealed that reflections hhl : 
l = 2n+1 were significantly weaker than reflections hhl : l = 2n. 
Such evidence led us to reduce the symmetry and re-index the 
3D diffraction patterns by a C-centered orthorhombic cell with 
approximate parameters a = 10.5 Å, b = 10.5 Å, c = 13.7 Å (Figure 
2). Potential extinctions pointed to space groups Cccm (66). This 
second trial allowed us to obtain an interpretable potential map 
where the orthocetamol molecule could be recognized. Yet, this 
pseudo-solution led to unphysical intermolecular distances and 
was evidently biased by too high symmetry constraints.  
Symmetry was therefore reduced to the monoclinic space 
group C2/c (15). The structure of orthocetamol was then able to 
be solved ab-initio by direct methods and later refined by least-
squares refinement (Figure 3a-c). All 11 non-hydrogen atoms 
were clearly recognizable in the potential map and were actually 
spotted by automatic routines. Atomic positions did not change 
significantly after least-squares refinement (see Figures S5 and 
S6). The choice of a monoclinic unit-cell was also supported by 
the successful indexing of the X-ray powder diffraction pattern, 
from which we obtained the refined lattice parameters: a = 
10.5612(2) Å, b = 10.3856(2) Å, c = 13.7176(2) Å, β = 93.113(2) °, 
V = 1502.37(3) Å3. Rietveld refinement on the same data and 
periodic DFT calculations additionally confirmed the structural 
model from ED (Figures S7 and S8). 






Figure 3. Orthocetamol structure and Fourier maps. a) View down [010] of 
orthocetamol structure superimposed to the Fourier map obtained after least-
squares refinement against 3D ED data. Fourier map allows for a clear atomic 
resolution. b) View down [001] of orthocetamol structure. c) View down [110] of 
orthocetamol structure, showing the alternated layered packing of molecular 
ribbons. d) Two orthocetamol molecules belonging to the same ribbon, next to 
the main residual detected in the difference Fourier map (in yellow), after all 
hydrogen atoms were removed. The residual clearly indicates the position of the 
hydroxylic hydrogen atom involved in the hydrogen bond (dashed red line). 
Our results show that the orthocetamol crystal structure 
consists of almost flat molecules that stretch along [110] and [1-
10] in an alternated layered manner (Figure 3c). Notably, some 
hydrogen atoms were also visible in the difference Fourier map, 
even without dynamical structure refinement.[16] In particular, the 
hydroxylic hydrogen, involved in an hydrogen bond, showed a 
potential comparable with the non-hydrogen atoms of the 
structure and could in fact be determined ab-initio (Figure 3d). 
 Intermolecular hydrogen bonds involving the hydroxy and 
carbonyl groups of adjacent molecules form infinite ribbons. This 
packing motif is also seen for the chlorinated analogues 2-
acetamido-4-chlorophenol and acetamido-5-chlorophenol, in the 
same space group but in less dense forms.[17]  
The OH∙∙∙O based supramolecular chain is a typical motif 
seen also in para- and metacetamol.[14] In all three paracetamol 
polymorphs, however, NH∙∙∙OH interactions are also present and 
laterally connect adjacent chains to form 2D sheets.[14a-c] Spirally 
arranged NH∙∙∙OH interactions are instead responsible for the 
formation of a 3D supramolecular network in the orthorhombic 
polymorph of metacetamol.[14d] The NH∙∙∙OH interaction is absent 
in the monoclinic polymorph of metacetamol.[14e]  
In the crystal structure of orthocetamol, chain alternation 
causes the NH donors to always point towards the aromatic rings 
and therefore they do not establish any relevant intermolecular 
interaction (Figure S6c). This molecular geometry seems then to 
prevent the hydroxyl group from being an effective acceptor of 
intermolecular H-bonds, and it is rather involved in an 
intramolecular NH∙∙∙OH interaction.  
Least-square refinement against ED data also confirmed 
the presence of twinning on a scale of about 150-200 nm, which 
produces a rotation of the structure of about 90° around the 
crystallographic axis c. Due to the resemblance of the cell 
dimensions a and b, pseudo-merohedric twinning mimics a 
tetragonal symmetry and brings intensities to otherwise extinct 
reflections. 
To our knowledge, orthocetamol is the first purely organic 
pharmacological compound whose structure could be solved by 
ED and could not be solved by X-ray diffraction. The lack of 
structural solution via X-ray techniques is due to the fact that 
orthocetamol forms crystalline domains of only a few hundreds of 
nanometers, which are moreover affected by disorder and 
twinning. The occurrence of pseudo-symmetry further hinders 
structure analysis by conventional techniques. This structure 
determination of orthocetamol definitively shows that 3D ED can 
be used for solving ab-initio pharmaceutical structures that could 
not be unveiled by X-ray methods. We believe that orthocetamol 
will be the harbinger of widespread application of 3D ED for all 
pharmaceutical cases where structure determination by X-ray 
diffraction, TEM imaging and crystal structure prediction are not 
successful or simply cannot be applied. Additionally, as already 
displayed for MicroED protocol,[10c,d] 3D ED may prove to be a 
very fast and efficient method for the screening of synthetic 
products and intermediates, even when available only in scant 
quantity or as polyphasic or polymorphic mixtures. 
Experimental Section 
Orthocetamol (Sigma Aldrich, A7000) was recrystallized 
from cyclohexanol according to a previously published method.[18] 
Details of analytical methods and instrumentation are provided in 
the Supplementary Information. 
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